Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis.

[1]  N. Pavlidis,et al.  Carcinoma of Unknown Primary (CUP) , 2014 .

[2]  N. Pavlidis,et al.  Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. , 2009, Seminars in oncology.

[3]  P. Schőffski,et al.  Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial , 2008, British Journal of Cancer.

[4]  Jeroen P Jansen,et al.  Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[5]  Georgia Salanti,et al.  Evaluation of networks of randomized trials , 2008, Statistical methods in medical research.

[6]  E. Felip,et al.  Cancers of unknown primary site: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Julian P T Higgins,et al.  Recent developments in meta‐analysis , 2008, Statistics in medicine.

[8]  T. Economopoulos,et al.  Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group phase II study , 2008, Acta oncologica.

[9]  Nikolaos A Patsopoulos,et al.  Uncertainty in heterogeneity estimates in meta-analyses , 2007, BMJ : British Medical Journal.

[10]  M. O'Rourke,et al.  Results of a Phase II Study of Weekly Paclitaxel Plus Carboplatin in Advanced Carcinoma of Unknown Primary Origin: A Reasonable Regimen for the Community-Based Clinic? , 2007, Cancer investigation.

[11]  C. Porta,et al.  Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site , 2006, Cancer.

[12]  Deborah M Caldwell,et al.  Simultaneous comparison of multiple treatments: combining direct and indirect evidence , 2005, BMJ : British Medical Journal.

[13]  P. Philip,et al.  A Phase II Study of Carboplatin and Paclitaxel in Adenocarcinoma of Unknown Primary , 2005, American journal of clinical oncology.

[14]  Yeon-Hee Park,et al.  A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site. , 2004, Japanese journal of clinical oncology.

[15]  G. Lu,et al.  Combination of direct and indirect evidence in mixed treatment comparisons , 2004, Statistics in medicine.

[16]  P. Petrow,et al.  Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[18]  J. Hainsworth,et al.  Diagnostic and therapeutic management of cancer of an unknown primary. , 2003, European journal of cancer.

[19]  J. Ioannidis,et al.  Levels of absolute survival benefit for systemic therapies of advanced cancer. a call for standards. , 2003, European journal of cancer.

[20]  L. Assersohn,et al.  A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary. , 2003, European journal of cancer.

[21]  David H. Johnson,et al.  A randomized Phase II trial in patients with carcinoma of an unknown primary site , 2001, Cancer.

[22]  N. Pavlidis,et al.  Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Falkson,et al.  Mitomycin C, Epirubicin and Cisplatin versus Mitomycin C Alone as Therapy for Carcinoma of Unknown Primary Origin , 1998, Oncology.

[24]  M. Tattersall,et al.  Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens. , 1987, European journal of cancer & clinical oncology.

[25]  T. Therneau,et al.  Lack of Value for Cisplatin Added to Mitomycin‐Doxorubicin Combination Chemotherapy for Carcinoma of Unknown Primary Site A Randomized Trial , 1987, American journal of clinical oncology.

[26]  M. Tattersall,et al.  Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens. , 1980, The New England journal of medicine.

[27]  E. Felip,et al.  Cancers of unknown primary site: ESMO clinical recommendation for diagnosis, treatment and follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  J. Coebergh,et al.  Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. , 2002, European journal of cancer.

[29]  C. Muir.  Cancer of unknown primary site , 1995, Cancer.

[30]  Alex Martinez.  A call for standards , 1987 .

[31]  S. Balcerzak,et al.  Management of patients with metastatic adenocarcinoma of unknown origin: a Southwest Oncology Group study. , 1983, Cancer treatment reports.